# A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

> **NCT03428958** · PHASE1,PHASE2 · COMPLETED · sponsor: **NuCana plc** · enrollment: 111 (actual)

## Conditions studied

- Colorectal Cancer
- Colorectal Neoplasms
- Colorectal Carcinoma
- Colorectal Tumors
- Neoplasms, Colorectal

## Interventions

- **DRUG:** NUC-3373 + leucovorin
- **DRUG:** NUC-3373
- **DRUG:** NUFOX
- **DRUG:** NUFOX + VEGF pathway inhibitor
- **DRUG:** NUFOX + EGFR inhibitor
- **DRUG:** NUFIRI
- **DRUG:** NUFIRI + VEGF pathway inhibitor
- **DRUG:** NUFIRI + EGFR inhibitor
- **DRUG:** NUC-3373 + bevacizumab

## Key facts

- **NCT ID:** NCT03428958
- **Lead sponsor:** NuCana plc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-05
- **Primary completion:** 2024-03-19
- **Final completion:** 2024-03-21
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03428958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03428958, "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03428958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*